Gosogliptin

Gosogliptin (INN; trade name Saterex) is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors (also called gliptins). It was discovered^[1] and developed through Phase 1^[2][3][4] and Phase 2^[5][6][7] by Pfizer. The crystal structure of DPP-4 in complex with gosogliptin is available.^[8] Its metabolism, excretion and pharmacokinetics in rat, dog and human have been described.^[9] A cost efficient route has been published.^[10] Other studies^[11] including Phase 3 studies were conducted in Russia.^[12][13] It is approved for use in Russia.^[14]

Other namesPF-734200

CAS Number

• 869490-23-3

PubChem CID

• 11516136

DrugBank

• DB08382

Quick facts Clinical data, Other names ...

Gosogliptin
INN: Gosogliptin

Clinical data
Other names	PF-734200
Identifiers
IUPAC name (3,3-Difluoro-1-pyrrolidinyl){(2S,4S)-4-[4-(2-pyrimidinyl)-1-piperazinyl]-2-pyrrolidinyl}methanone
CAS Number	869490-23-3
PubChem CID	11516136
DrugBank	DB08382
ChemSpider	9690926
UNII	GI718UO477
CompTox Dashboard (EPA)	DTXSID601007213
Chemical and physical data
Formula	C17H24F2N6O
Molar mass	366.417 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cnc(nc1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCC(C4)(F)F
InChI InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1 Key:QWEWGXUTRTXFRF-KBPBESRZSA-N

Close